You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
遠大醫藥(00512.HK)附屬擬4.4億元進一步收購重慶多普泰醫藥科技63%股權
格隆匯 01-15 18:43

格隆匯1月15日丨遠大醫藥(00512.HK)公吿,此前,集團附屬公司西安碑林藥業股份有限公司與重慶多普泰製藥股份有限公司(多普泰製藥)簽訂股權投資協議,據此,西安碑林將在投資協議約定的相關條件滿足後以不超過人民幣1.8954億元收購重慶多普泰醫藥科技有限公司27%的股權。

於2024年1月15日,買方及賣方達成第二次收購協定,賣方有條件下同意進一步出售及買方有條件下同意以人民幣4.4億元進一步收購目標公司重慶多普泰醫藥科技有限公司63%的股權。

於第二次收購協議完成後,買方將持有目標公司90%股權。

本次對於多普泰醫藥科技的收購,是集團在心腦血管疾病治療領域的一次重大產業佈局。心腦血管疾病治療領域是集團的傳統優勢領域之一,集團通過此次收購將豐富集團的產品管線,進一步鞏固和提升集團在心腦血管疾病治療領域的市場綜合競爭力,為集團業績的持續增長提供驅動力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account